We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1). We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers - SION-719 and SION-451 - evaluating the safety, tolerability and PK of single and multiple ascending doses of each product candidate in healthy subjects. These trials are randomized, doubled-blinded, placebo-controlled trials being conducted in Australia. As of January 14, 2025, five SAD cohorts and three MAD cohorts of SION-719 have been completed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the cutoff date of January 14, 2025. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function.